Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galunisertib + Gemcitabine in advanced pancreatic cancer
NCT02154646Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2014
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of galunisertib in pancreatic adenocarcinoma (PDAC), sponsored by Eli Lilly and Company. Primary endpoint: Dose-Limiting Toxicities. Started May 2014; status: completed.
02
Drugs
galunisertib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02154646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02154646.